Based on innovation and competitiveness, Korea's biopharmaceutical industry continues to grow thanks to advancements in production infrastructure, support for entering overseas markets, and greater investemnt in R&D.
Korea's Biopharmaceutical Industry Trends (2011-2015)
Market Scale / Production Amount
Exports / Imports
* Source: Ministry of Food and Drug Safety (2016)
Approval Status of New Drugs Developed in Korea (2015-2016)
By constatly expanding investment in R&D, Korea's biopharmaceutical industry has developed five new drugs in 2015 alone, and has received approval to develop 27 more as of December 2016.
|Product||Company||Main Substance||Efficay||Approval Date|
|Acelex Cap.||CrystalGenomics, Inc.||Polmacoxib||Osteoarthritis drug||Feb. 2, 2015|
|Zabolante Tab.||Dong-A ST Co., Ltd.||
|Antimicrobial (antibiotic) agent||Mar.3, 2015|
|Sivextro Tab.||Dong-A ST Co., Ltd.||Tedizolid phosphate||Antimicrobial (antibiotic) agent||Apr. 17, 2015|
|Suganon Tab.||Evogliptin tartrate||antidiabetic drug||Oct.2, 2015|
|Olita Tab.||Hanmi Pharmaceutical||Olmutinib HCL monohydrate||Cancer drug (lung cancer)||May 13, 2016|
* Source: Ministry of Food and Drug Safety press release (2016)